SCHEMBL2301805

SCHEMBL2301805

O=C(O)c1ccc(Cl)nc1OC(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.41
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
XPO1 O14980 1/20 0.37
KMO O15229 1/20 0.36
IGF1R P08069 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SORT1 Q99523 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RUNX1 Q01196 1/20 0.36
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2307983 0.83 GABRP (0.50) DHODHAKR1C2AKR1C1POLBTDP1
SCHEMBL23754012 0.83 TUBB4A (0.46) TDP1ALDH1A1LMNASMN1; SMN2
SCHEMBL2718290 0.80 L3MBTL1 (0.43) POLBTDP1XPO1GAAKMT2A
SCHEMBL28981525 0.78 PDCD1LG2 (0.36) XPO1IGF1RKMT2AALDH1A1LMNA
SCHEMBL6742273 0.77 TDP1 (0.66) AKR1C2POLBTDP1GAAKMT2A
SCHEMBL30437331 0.77 TDP1 (0.66) AKR1C2POLBTDP1GAAKMT2A
SCHEMBL23286918 0.77 POLB (0.40) POLBTDP1GAAKMT2AALDH1A1
SCHEMBL29737949 0.77 POLB (0.40) POLBTDP1GAAKMT2AALDH1A1
SCHEMBL19662158 0.74 PIN1 (0.43) POLBTDP1KMT2AALDH1A1
SCHEMBL29548245 0.74 PIN1 (0.43) POLBTDP1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 WO disclosed
CN-109956929-B Heterocyclic derivative, preparation method, pharmaceutical composition and application thereof 上海迪诺医药科技有限公司 2023-09-19 CN disclosed
CN-109956929-A Hete rocyclic derivatives, preparation method, pharmaceutical composition and application 上海迪诺医药科技有限公司 2019-07-02 CN disclosed
EP-2350008-A1 METHOD FOR THE PREPARATION OF FUNCTIONALIZED TRIHALOMETHOXY SUBSTITUTED PYRIDINES Bayer CropScience AG (DE) 2011-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B DHODH 3624/4885AKR1C2 1728/4885AKR1C1 2265/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B DHODH 3624/4885AKR1C2 1728/4885AKR1C1 2265/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B DHODH 3416/4885AKR1C2 573/4885AKR1C1 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.